COVID-19

Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space

NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in…

5 months ago

Rapid Dose Therapeutics Submits QuickStrip(TM) Nicotine Product for Health Canada Approval

Innovative Oral Nicotine Delivery Technology Targets Safer Alternative for SmokersBurlington, Ontario--(Newsfile Corp. - August 4, 2025) - Rapid Dose Therapeutics…

5 months ago

Hyperfine Achieves Clinical Milestone Ahead of Plan With 100th Patient Enrolled in Neurology Office Study Using the Next-Generation Swoop® System

NEURO PMR study evaluates the clinical utility and patient experience of AI-powered portable MRI in an outpatient settingGUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine,…

5 months ago

Hyperfine Achieves Clinical Milestone Ahead of Plan With 100th Patient Enrolled in Neurology Office Study Using the Next-Generation Swoop® System

NEURO PMR study evaluates the clinical utility and patient experience of AI-powered portable MRI in an outpatient settingGUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine,…

5 months ago

Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13)Updates 2025 projected…

5 months ago

UK Court of Appeal Confirms Moderna’s EP’949 Patent is Valid and Infringed by Pfizer/BioNTech

CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of…

5 months ago

Hemostemix Increases Previously Closed Private Placement to $3,000,000

Calgary, Alberta--(Newsfile Corp. - July 31, 2025) - Further to its press release dated July 24, 2025, Hemostemix Inc. (TSXV:…

5 months ago

Cells: Hemostemix ACP-01 Provides the Scientific Basis for Improving the Longevity and Signal Uptake of Brain Computer Implants

Calgary, Alberta--(Newsfile Corp. - July 31, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is…

5 months ago

AIM ImmunoTech Announces Closing of $8.0 Million Public Offering

OCALA, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (the “Company”), today announced the closing…

5 months ago

IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

Initiation of additional trial sites and patient enrollment activities ongoing with multiple patients in screening LAWRENCEVILLE, N.J., July 30, 2025…

5 months ago